Mark was compensated for his participation in this video.
From the research and development of symptomatic breakthrough treatment in the 1980s and 1990s, to our current, industry-leading, antibody developments, Eisai has long been at the forefront of Alzheimer's research. Our approach is marked by a drive to identify the root cause and stage of each person's disease so that we may provide the right intervention - including prevention - for the right person, at the right time. Read on to learn more.
View Eisai's Late-Breaking Symposium Presentation at the 2023 Clinical Trials on Alzheimer's Disease Conference
EISAI'S hhc COMMITMENT TO PATIENTS AND FAMILIES WITH AD AND DEMENTIA
"I WANT YOU TO SEE ME, NOT MY ALZHEIMER'S DISEASE." A PATIENT'S STORY BY PHOTOGRAPHER MARK TIMMONS.
Understanding Alzheimer's Disease Research
When analyzing the results of a trial, it’s critical to understand the context of the study design. In a LinkedIn Live stream, leading neurologists Sharon Cohen, MD, FRCPC, and David Weisman MD, joined Eisai’s Michael Irizarry, MD, MPH, SVP of Clinical Research and Deputy Chief Clinical Officer, Neurology, to discuss the real-world implications of study design methods and data evaluation in Alzheimer’s disease clinical research.
Perspectives from Global Experts on the Alzheimer’s Disease Patient Journey and Meaningfulness of Clinical Intervention
With new options for disease management on the horizon, clinicians, patients, and care partners can be better informed and equipped across the various stages of Alzheimer’s disease (AD). Presented at the 17th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2023), three experts from the United States, Canada, and Europe discuss the patient clinical care pathway in AD including the evolving diagnostic workflow; identifying appropriate patients and addressing their needs; and meaningful benefit and patient-relevant outcomes.
Defining Meaningful Benefits for Alzheimer’s Disease Patients & Care Partners Along the Clinical Care Journey
The demonstration of meaningful benefits across Alzheimer’s disease (AD) patients, clinicians, and care partners is undeniably critical and varies across different stages of the clinical care journey. Thus, identifying meaningfulness benefits is imperative to move towards slowing disease progression or disease management. Presented at the 2022 Alzheimer’s Association International Conference (AAIC), four leading experts describe AD patient perspectives in the contexts of timely diagnostic journey, biomarker utility in AD diagnosis and management, and provide guidance to healthcare professionals that may be helpful when communicating the most relevant outcomes to AD patients and care partners.
A BLOOD TEST FOR ALZHEIMER’S?
We’re collaborating with Sysmex on a potential blood-based test for predicting amyloid pathology. This automated immune-assay system under investigation could also be utilized as a simpler and more cost-effective method to identify participants for clinical trials exploring a variety of AD therapies now in development.